New immune drug OSE-279 takes on advanced tumors

NCT ID NCT05751798

Recruiting now Disease control Sponsor: OSE Immunotherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well the drug shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA NSCLC (NON-SMALL CELL LUNG CANCER) SOLID ADVANCED TUMOR

Contacts and locations

Locations

Antwerp University Hospital
RECRUITING

Edegem, 11013, Belgium
Centre Eugène Marquis
COMPLETED

Rennes, 35000, France
Centre Léon Bérard
RECRUITING

Lyon, 69373, France
Hopital Saint Joseph
RECRUITING

Paris, 75014, France
Hospital Regional Universitario de Málaga
RECRUITING

Málaga, 2901, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Institut Jules Bordet
RECRUITING

Anderlecht, 1070, Belgium
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI)
RECRUITING

Girona, 17007, Spain
Institut de Cancerologie de l'Ouest
RECRUITING

Saint-Herblain, 44805, France
Oncopole
RECRUITING

Toulouse, 31059, France
University Hospital A Coruña Biomedical Research Institute (INIBIC)
RECRUITING

A Coruña, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.